Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Hypera
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	R$23.56
52 Haftanın En Yüksek Seviyesi	R$28.87
52 Haftanın En Düşük Seviyesi	R$17.61
Beta	0.25
1 Aylık Değişim	-12.06%
3 Aylık Değişim	3.93%
1 Yıllık Değişim	31.47%
3 Yıllık Değişim	-45.37%
5 Yıllık Değişim	-33.28%
Halka arzdan bu yana değişim	182.16%

Son Haberler & Güncellemeler

Hypera (BVMF:HYPE3) Takes On Some Risk With Its Use Of Debt

Dec 28

What You Can Learn From Hypera S.A.'s (BVMF:HYPE3) P/E

Dec 01

Hypera's (BVMF:HYPE3) Anemic Earnings Might Be Worse Than You Think

Nov 05

Recent updates

Hypera (BVMF:HYPE3) Takes On Some Risk With Its Use Of Debt

Dec 28

What You Can Learn From Hypera S.A.'s (BVMF:HYPE3) P/E

Dec 01

Hypera's (BVMF:HYPE3) Anemic Earnings Might Be Worse Than You Think

Nov 05

Does Hypera (BVMF:HYPE3) Have A Healthy Balance Sheet?

Sep 05

Hypera S.A. Just Beat EPS By 8.0%: Here's What Analysts Think Will Happen Next

Aug 10

The Price Is Right For Hypera S.A. (BVMF:HYPE3)

Jun 15

Does Hypera (BVMF:HYPE3) Have A Healthy Balance Sheet?

Apr 23

Hypera's (BVMF:HYPE3) Weak Earnings May Only Reveal A Part Of The Whole Picture

Mar 27

Product Expansion And Investments In Chronic Treatments Will Strengthen Future Operations

Mar 23 Hypera's working capital focus will improve cash flow, enhancing net margins and financial stability through inventory and operational efficiency enhancements.

Why Investors Shouldn't Be Surprised By Hypera S.A.'s (BVMF:HYPE3) P/E

Feb 24

More Unpleasant Surprises Could Be In Store For Hypera S.A.'s (BVMF:HYPE3) Shares After Tumbling 27%

Nov 21

We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt

Nov 14

Investors Appear Satisfied With Hypera S.A.'s (BVMF:HYPE3) Prospects

Oct 03

We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt

Jul 13

Hypera S.A.'s (BVMF:HYPE3) Popularity With Investors Is Under Threat From Overpricing

Jun 20

Hypera S.A. (BVMF:HYPE3) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 16

Is Hypera (BVMF:HYPE3) A Risky Investment?

Feb 21

Here's Why Hypera (BVMF:HYPE3) Has Caught The Eye Of Investors

Jan 09

Hypera S.A.'s (BVMF:HYPE3) Business Is Yet to Catch Up With Its Share Price

Dec 22

Hypera (BVMF:HYPE3) Has A Somewhat Strained Balance Sheet

Nov 02

Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?

Aug 27

Is Hypera (BVMF:HYPE3) A Risky Investment?

Jul 21

We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt

Apr 15

With EPS Growth And More, Hypera (BVMF:HYPE3) Makes An Interesting Case

Feb 19

We Think Hypera (BVMF:HYPE3) Can Stay On Top Of Its Debt

Jan 03

Is Now The Time To Put Hypera (BVMF:HYPE3) On Your Watchlist?

Oct 11

Hypera S.A. (BVMF:HYPE3) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Jul 31

Is Hypera (BVMF:HYPE3) Using Too Much Debt?

Jul 19

Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?

Jun 28

Here's Why Hypera (BVMF:HYPE3) Can Manage Its Debt Responsibly

Apr 14

I Ran A Stock Scan For Earnings Growth And Hypera (BVMF:HYPE3) Passed With Ease

Mar 25

Subdued Growth No Barrier To Hypera S.A.'s (BVMF:HYPE3) Price

Mar 04

Hissedar Getirileri

	HYPE3	BR Pharmaceuticals	BR Pazar
7D	0.9%	0.7%	0.3%
1Y	31.5%	8.0%	21.0%

Getiri vs. Endüstri: HYPE3 geçen yıl % 8 oranında getiri sağlayan BR Pharmaceuticals sektörünü aştı.

Getiri vs Piyasa: HYPE3 geçen yıl % 21 oranında getiri sağlayan BR Piyasasını aştı.

Fiyat Oynaklığı

Is HYPE3's price volatile compared to industry and market?
HYPE3 volatility
HYPE3 Average Weekly Movement	4.7%
Pharmaceuticals Industry Average Movement	5.1%
Market Average Movement	4.5%
10% most volatile stocks in BR Market	9.1%
10% least volatile stocks in BR Market	1.6%

İstikrarlı Hisse Senedi Fiyatı: HYPE3 son 3 ayda BR piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: HYPE3 'nin haftalık oynaklığı ( 5% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1999	10,481	Breno Pires de Oliveira	www.hypera.com.br

Hypera S.A. Brezilya'da bir ilaç şirketi olarak faaliyet göstermektedir. Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR adı altında reçeteli ürünler sunmaktadır, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex - A, Nesina, Novotram, oximax, peridal, Peridal Süspansiyon, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma ve velunid markaları.

Hypera S.A. Temel Bilgiler Özeti

Hypera'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
HYPE3 temel i̇stati̇sti̇kler
Piyasa değeri	R$14.91b
Kazançlar(TTM)	R$825.30m
Gelir(TTM)	R$6.97b

18.1x

F/K Oranı

2.1x

P/S Oranı

HYPE3 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
HYPE3 gelir tablosu (TTM)
Gelir	R$6.97b
Gelir Maliyeti	R$3.02b
Brüt Kâr	R$3.95b
Diğer Giderler	R$3.13b
Kazançlar	R$825.30m

Son Raporlanan Kazançlar

Sep 30, 2025

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	1.30
Brüt Marj	56.70%
Net Kâr Marjı	11.84%
Borç/Özkaynak Oranı	74.7%

HYPE3 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

5.0%

Mevcut Temettü Verimi

104%

Ödeme Oranı

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/01/02 13:51
Gün Sonu Hisse Fiyatı	2025/12/30 00:00
Kazançlar	2025/09/30
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Hypera S.A. 22 Bu analistlerden 13, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Andréa Aznar	BB Banco de Investimento S.A.
Robert Ford Aguilar	BofA Global Research
Marcio Osako	Bradesco S.A. Corretora de Títulos e Valores Mobiliários

Hypera (HYPE3) Hisse Özeti

Ödüller

Risk Analizi

Working Capital Optimization And Neosaldina Launches Will Shape Future Operations

Brazil Pricing Pressures And Aging Workforce Will Erode Margins

Aging Population And Rising Middle Class Will Drive Healthcare Expansion

Hypera S.A. Rakipler

Ouro Fino Saúde Animal Participações

Pfizer

Apeloa PharmaceuticalLtd

Zhejiang Jiuzhou Pharmaceutical

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Hypera (BVMF:HYPE3) Takes On Some Risk With Its Use Of Debt

What You Can Learn From Hypera S.A.'s (BVMF:HYPE3) P/E

Hypera's (BVMF:HYPE3) Anemic Earnings Might Be Worse Than You Think

New minor risk - Earnings quality

Recent updates

Hypera (BVMF:HYPE3) Takes On Some Risk With Its Use Of Debt

What You Can Learn From Hypera S.A.'s (BVMF:HYPE3) P/E

Hypera's (BVMF:HYPE3) Anemic Earnings Might Be Worse Than You Think

New minor risk - Earnings quality

Third quarter 2025 earnings: EPS misses analyst expectations

Does Hypera (BVMF:HYPE3) Have A Healthy Balance Sheet?

Hypera S.A. Just Beat EPS By 8.0%: Here's What Analysts Think Will Happen Next

Second quarter 2025 earnings: EPS exceeds analyst expectations

Price target increased by 8.8% to R$28.20

The Price Is Right For Hypera S.A. (BVMF:HYPE3)

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

New minor risk - Profit margin trend

Does Hypera (BVMF:HYPE3) Have A Healthy Balance Sheet?

New major risk - Financial position

Hypera's (BVMF:HYPE3) Weak Earnings May Only Reveal A Part Of The Whole Picture

Hypera S.A., Annual General Meeting, Apr 25, 2025

Product Expansion And Investments In Chronic Treatments Will Strengthen Future Operations

Full year 2024 earnings: EPS and revenues miss analyst expectations

Why Investors Shouldn't Be Surprised By Hypera S.A.'s (BVMF:HYPE3) P/E

Hypera S.A. to Report Q3, 2025 Results on Oct 29, 2025

Price target decreased by 8.1% to R$27.83

Hypera S.A. to Report Fiscal Year 2024 Results on Mar 20, 2025

More Unpleasant Surprises Could Be In Store For Hypera S.A.'s (BVMF:HYPE3) Shares After Tumbling 27%

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt

Price target decreased by 8.4% to R$33.76

Consensus EPS estimates fall by 11%

Investors Appear Satisfied With Hypera S.A.'s (BVMF:HYPE3) Prospects

Second quarter 2024 earnings: EPS exceeds analyst expectations

We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt

Now 27% undervalued after recent price drop

Now 22% undervalued after recent price drop

Hypera S.A.'s (BVMF:HYPE3) Popularity With Investors Is Under Threat From Overpricing

Now 23% undervalued after recent price drop

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Now 21% undervalued after recent price drop

Hypera S.A., Annual General Meeting, Apr 23, 2024

Hypera S.A. (BVMF:HYPE3) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Full year 2023 earnings: EPS and revenues miss analyst expectations

Is Hypera (BVMF:HYPE3) A Risky Investment?

Hypera S.A. to Report Q3, 2024 Results on Nov 06, 2024

Here's Why Hypera (BVMF:HYPE3) Has Caught The Eye Of Investors

Hypera S.A.'s (BVMF:HYPE3) Business Is Yet to Catch Up With Its Share Price

Hypera (BVMF:HYPE3) Has A Somewhat Strained Balance Sheet

Third quarter 2023 earnings: EPS exceeds analyst expectations

Now 21% undervalued after recent price drop

Do Hypera's (BVMF:HYPE3) Earnings Warrant Your Attention?

New major risk - Financial position

Second quarter 2023 earnings released: EPS: R$0.79 (vs R$0.72 in 2Q 2022)

Is Hypera (BVMF:HYPE3) A Risky Investment?

First quarter 2023 earnings released

We Think Hypera (BVMF:HYPE3) Is Taking Some Risk With Its Debt

With EPS Growth And More, Hypera (BVMF:HYPE3) Makes An Interesting Case

Full year 2022 earnings released: EPS: R$2.69 (vs R$2.56 in FY 2021)

Hypera S.A. to Report Q4, 2022 Results on Feb 16, 2023

We Think Hypera (BVMF:HYPE3) Can Stay On Top Of Its Debt

Less than half of directors are independent

Third quarter 2022 earnings released

Is Now The Time To Put Hypera (BVMF:HYPE3) On Your Watchlist?

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Hypera S.A. (BVMF:HYPE3) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Is Hypera (BVMF:HYPE3) Using Too Much Debt?